Evidence shows that the activation of RTK and its downstream signaling effectors promotes the proliferation of ER(+) breast cancer cells independent of ER activity, and the alteration of transcription factors other than ER is considered as a potential mechanism of endocrine resistance. This evidence concerns the gene ESR1 and breast carcinoma.